Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rosuvastatin 5 mg versus pravastatin 40 mg and atorvastatin 10 mg in type IIa/IIb hypercholesterolemia
2006-006697-15Phase 4Completed
- Sponsor
- AstraZeneca
- Start
- Feb 2007
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4 trial of rosuvastatin, pravastatin and atorvastatin in hypercholesterolemia (3 arms), sponsored by AstraZeneca. Primary endpoint: Percent change from baseline in LDL cholesterol at 8 weeks. Started Feb 2007; status: completed.
02
Drugs
rosuvastatinpravastatinatorvastatin
03
Conditions
hypercholesterolemia
Beyond the preview
Go deeper on 2006-006697-15.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-006697-15.